UNCY earnings: next report 2026-08-13, real EPS beat/miss history, analyst consensus Buy, P/E -2.72. Updated 2026-07-23.
Unicycive Therapeutics (UNCY) Research Hub
Unicycive Therapeutics (UNCY) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 5.29 USD (+3.32%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -2.72, market cap 0.12B. This hub links to the full technical, earnings and options research available for UNCY.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 5.29 USD (+3.32%) |
| 52-week range | 3.93 USD – 8.43 USD |
| Trend regime | Range |
| 14-day RSI | 55.3 (Bullish) |
| Trailing P/E | -2.72 |
| Market cap | 0.12B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for UNCY
Covered Call on UNCY: how it works, illustrative setup around the real 5.29 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on UNCY: how it works, illustrative setup around the real 5.29 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on UNCY: how it works, illustrative setup around the real 5.29 USD price, max profit/loss, breakeven and when to use it. Educational.
UNCY technical analysis: range, last 5.29 USD, RSI 55.3, 52w range 3.93 USD–8.43 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is UNCY in?
Unicycive Therapeutics (UNCY) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is UNCY in an uptrend or downtrend?
As of 2026-09-11, UNCY is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is UNCY's trailing P/E ratio?
UNCY's trailing P/E is -2.72, with a market cap of 0.12B. See the earnings research page for full valuation detail.
When does UNCY next report earnings?
UNCY is next scheduled to report earnings on 2026-08-13, with a consensus EPS estimate of -0.471 USD.